Chronic Total Occlusion of Coronary Left Main Artery Supplied by Right Collaterals under Vascular Endothelial Growth Factor Inhibitor Therapy
Published: 2023-08-18
Page: 328-332
Issue: 2023 - Volume 6 [Issue 1]
K. Chawki *
Department of Cardiology, IBN Rochd University Hospital, Morocco.
E. M. Rochd
Department of Cardiology, IBN Rochd University Hospital, Morocco.
M. Selmaoui
Department of Cardiology, IBN Rochd University Hospital, Morocco.
A. El Jazouli
Department of Cardiology, IBN Rochd University Hospital, Morocco.
M. Haboub
Department of Cardiology, IBN Rochd University Hospital, Morocco.
S. Arous
Department of Cardiology, IBN Rochd University Hospital, Morocco.
G. Bennouna
Department of Cardiology, IBN Rochd University Hospital, Morocco.
A. Drighil
Department of Cardiology, IBN Rochd University Hospital, Morocco.
R. Habbal
Department of Cardiology, IBN Rochd University Hospital, Morocco.
*Author to whom correspondence should be addressed.
Abstract
We report a rare case of a patient who despite being under anti VEGF : Bevacizumab , developed a large coronary collateral circulation completely supplying the chronic total occlusion of left main coronary artery.
Bevacizumab, a monoclonal antibody was the first potent angiogenic inhibitor , targeting vascular endothelial growth factor (VEGF)-A.
Some of it's important cardiovascular adverse events include arterial and venous thrombotic events, coronary artery disease and heart failure resulting from inhibition of endothelial regeneration.
Our patient developed dyspnea after 1 year of receiving bevacizumab with a chronic total occlusion of the left main coronary artery with the particularity of developing extensive collaterals despite the anti VEGF treatment she received.
Keywords: Coronary artery disease, vascular endothelial growth, myocardial dysfunction, Bevacizumab